Sugi Predict

Sugi Predict / Compounds / SCHEMBL2884751

SCHEMBL2884751

SCHEMBL2884751

Cc1ccc2c(Br)c(F)ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ CYP1A2 P05177 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ KDM1A O60341 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ PDE7A Q13946 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ CCR1 P32246 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CCR5 P51681 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556360 1.00 ALDH1A1 (0.41) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL4058945 0.80 ALDH1A1 (0.43) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL14573267 0.80 ALDH1A1 (0.51) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL9248212 0.80 ALDH1A1 (0.43) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL4357760 0.77 ESR1 (0.56) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL4659301 0.77 KDM4E (0.44) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL11001297 0.77 LMNA (0.46) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL5215349 0.77 ALDH1A1 (0.41) ALDH1A1CYP1A2KDM4ELMNAPOLB
SCHEMBL1133977 0.77 NT5E (0.34) KDM4EESR1ESR2
SCHEMBL564237 0.77 KDM4E (0.44) ALDH1A1CYP1A2KDM4ELMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0245913-B1 Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid RIKER LABORATORIES, INC. (US) 1992-03-25 — — EP claimed
US-4898945-A Process for 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-02-06 — — US claimed
EP-0245913-A1 Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid RIKER LABORATORIES, INC. (US) 1987-11-19 — — EP claimed
EP-0119779-A1 8-Alkoxy-6,7-dihydro-5-methyl-9-fluoro-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acids RIKER LABORATORIES, INCORPORATED (US) 1984-09-26 — — EP claimed
JP-7300461-A — — None — — JP disclosed
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 — — US disclosed
WO-2025068943-A1 KAT6 INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-04-03 — — WO disclosed
US-20100204273-A1 Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors GLAXO GROUP LIMITED 2010-08-12 — — US disclosed
US-7732600-B2 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors GLAXO GROUP LIMITED (GB) 2010-06-08 — — US disclosed
EP-2145622-A1 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors Glaxo Group Limited (GB) 2010-01-20 — — EP disclosed
US-20090312546-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS GLAXO GROUP LIMITED 2009-12-17 — — US disclosed
EP-1876174-B1 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors GLAXO GROUP LTD (GB) 2009-11-11 — — EP disclosed
US-4898945-A Process for 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-02-06 — — US disclosed
EP-0245913-A1 Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid RIKER LABORATORIES, INC. (US) 1987-11-19 — — EP disclosed
US-4568750-A 1-ACETYL-5-BROMO-6-FLUORO-1,2,3,4-TETRAHYDROQUINALDINE RIKER LABORATORIES, INC. (US) 1986-02-04 — — US disclosed
US-4568750-A 1-ACETYL-5-BROMO-6-FLUORO-1,2,3,4-TETRAHYDROQUINALDINE RIKER LABORATORIES, INC. (US) 1986-02-04 — — US disclosed
US-4552879-A BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1985-11-12 — — US disclosed
EP-0119779-A1 8-Alkoxy-6,7-dihydro-5-methyl-9-fluoro-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acids RIKER LABORATORIES, INCORPORATED (US) 1984-09-26 — — EP disclosed
US-4472407-A Antimicrobial 8-alkoxy-6,7-dihydro-5-methyl-9-fluoro-1-oxo-1H,5H-benzo[ij]qu RIKER LABORATORIES, INC. (US) 1984-09-18 — — US disclosed
US-4399134-A BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204273-A1 Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors OPRK1, OPRL1, OPRD1 ALDH1A1 2366/4885CYP1A2 869/4885KDM4E 4131/4885
US-20090312546-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS HTR1A, HTR1D, HTR1F ALDH1A1 3105/4885CYP1A2 417/4885KDM4E 3665/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 ALDH1A1 3555/4885CYP1A2 3644/4885KDM4E 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.